Cantargia Ab

Cantargia Ab company information, Employees & Contact Information

Explore related pages

Related company profiles:

Cantargia develops antibody based therapies against the target IL1RAP. The two clinical programs are nadunolimab in phase II development for treatment of cancer, and CAN10 in phase I development for autoimmune/inflammatory diseases.

Company Details

Employees
30
Founded
-
Address
Scheelevägen 27, Lund,skåne County 22363,sweden
Phone
46 4 62 75 62 60
Email
in****@****gia.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Lund, Skåne County
Looking for a particular Cantargia Ab employee's phone or email?

Cantargia Ab Questions

News

Cantargia to Participate in Upcoming Conferences - Yahoo Finance

Cantargia to Participate in Upcoming Conferences Yahoo Finance

Cantargia to Participate in Upcoming Conferences - TradingView

Cantargia to Participate in Upcoming Conferences TradingView

Cantargia Announces the Acquisition of its CAN10 IL1RAP Immunology Program by Otsuka Pharmaceutical - Yahoo Finance

Cantargia Announces the Acquisition of its CAN10 IL1RAP Immunology Program by Otsuka Pharmaceutical Yahoo Finance

Cantargia closes the acquisition of CAN10 by Otsuka - Finansavisen

Cantargia closes the acquisition of CAN10 by Otsuka Finansavisen

Cantargia Presents Data at an AACR Conference Strengthening IL1RAP as a Targetable Hallmark in PDAC - Yahoo Finance

Cantargia Presents Data at an AACR Conference Strengthening IL1RAP as a Targetable Hallmark in PDAC Yahoo Finance

Cantargia granted important US patent for nadunolimab - Finansavisen

Cantargia granted important US patent for nadunolimab Finansavisen

Otsuka to acquire Cantargia’s CAN10 for autoimmune diseases - Pharmaceutical Technology

Otsuka to acquire Cantargia’s CAN10 for autoimmune diseases Pharmaceutical Technology

Cantargia presents clinical interim results at ASCO 2022 highlighting the potential of nadunolimab in combination with c - Notimérica

Cantargia presents clinical interim results at ASCO 2022 highlighting the potential of nadunolimab in combination with c Notimérica

Otsuka bets on Cantargia in deal worth up to $613 million - The Pharma Letter

Otsuka bets on Cantargia in deal worth up to $613 million The Pharma Letter

Cantargia Appoints Dr Hilde Steineger as Chief Executive Officer - Yahoo Finance

Cantargia Appoints Dr Hilde Steineger as Chief Executive Officer Yahoo Finance

Cantargia resolves on a fully covered rights issue of approximately SEK 250 million (1) - Europa Press

Cantargia resolves on a fully covered rights issue of approximately SEK 250 million (1) Europa Press

Cantargia presents new robust data at ASCO 2022 confirming promising effects of nadunolimab in treatment of pancreatic c - Notimérica

Cantargia presents new robust data at ASCO 2022 confirming promising effects of nadunolimab in treatment of pancreatic c Notimérica

Cantargia Announces Preliminary Topline Efficacy Results From the Phase 2 TRIFOUR Trial of Nadunolimab in Advanced Triple-Negative Breast Cancer (TNBC) - Yahoo Finance

Cantargia Announces Preliminary Topline Efficacy Results From the Phase 2 TRIFOUR Trial of Nadunolimab in Advanced Triple-Negative Breast Cancer (TNBC) Yahoo Finance

Cantargia Announces Publication of Clinical Data Showing Benefit of Nadunolimab Combination Therapy in Advanced Lung Cancer - Yahoo Finance

Cantargia Announces Publication of Clinical Data Showing Benefit of Nadunolimab Combination Therapy in Advanced Lung Cancer Yahoo Finance

Cantargia’s Nadunolimab Aantibody Awarded US FDA Fast Track Designation - Yahoo Finance

Cantargia’s Nadunolimab Aantibody Awarded US FDA Fast Track Designation Yahoo Finance

Cantargia's CAN10 demonstrates positive activity in systemic sclerosis models in new data presented at ACR Convergence 2 - Europa Press

Cantargia's CAN10 demonstrates positive activity in systemic sclerosis models in new data presented at ACR Convergence 2 Europa Press

Cantargia: ASCO 2022 presentation strengthens positive phase IIa interim results for nadunolimab in NSCLC - Europa Press

Cantargia: ASCO 2022 presentation strengthens positive phase IIa interim results for nadunolimab in NSCLC Europa Press

Top Cantargia Ab Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant